- Home
- HAFN vs NVCR Comparison
HAFN vs NVCR Comparison
Compare HAFN & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HAFN
- NVCR
- Stock Information
- Founded
- HAFN 2012
- NVCR 2000
- Country
- HAFN Singapore
- NVCR Switzerland
- Employees
- HAFN N/A
- NVCR N/A
- Industry
- HAFN
- NVCR Medical/Dental Instruments
- Sector
- HAFN
- NVCR Health Care
- Exchange
- HAFN Nasdaq
- NVCR Nasdaq
- Market Cap
- HAFN 2.1B
- NVCR 1.9B
- IPO Year
- HAFN N/A
- NVCR 2015
- Fundamental
- Price
- HAFN $5.04
- NVCR $17.38
- Analyst Decision
- HAFN Strong Buy
- NVCR Buy
- Analyst Count
- HAFN 1
- NVCR 6
- Target Price
- HAFN $6.50
- NVCR $32.83
- AVG Volume (30 Days)
- HAFN 1.5M
- NVCR 884.7K
- Earning Date
- HAFN 05-27-2025
- NVCR 04-24-2025
- Dividend Yield
- HAFN 22.97%
- NVCR N/A
- EPS Growth
- HAFN N/A
- NVCR N/A
- EPS
- HAFN 1.50
- NVCR N/A
- Revenue
- HAFN $2,868,647,000.00
- NVCR $621,711,000.00
- Revenue This Year
- HAFN N/A
- NVCR $2.90
- Revenue Next Year
- HAFN $1.48
- NVCR $10.47
- P/E Ratio
- HAFN $3.23
- NVCR N/A
- Revenue Growth
- HAFN 7.37
- NVCR 18.27
- 52 Week Low
- HAFN $3.61
- NVCR $14.17
- 52 Week High
- HAFN $8.99
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- HAFN N/A
- NVCR 48.17
- Support Level
- HAFN N/A
- NVCR $16.19
- Resistance Level
- HAFN N/A
- NVCR $17.70
- Average True Range (ATR)
- HAFN 0.00
- NVCR 0.85
- MACD
- HAFN 0.00
- NVCR 0.06
- Stochastic Oscillator
- HAFN 0.00
- NVCR 42.53
About HAFN Hafnia Limited Common Shares
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
About NVCR NovoCure Limited
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.